Drug Profile
Research programme: long-acting injectable products - MedinCell/Sandoz
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator MedinCell S.A.; Sandoz
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Cancer in European Union (Parenteral, Injection)
- 04 Feb 2016 Early research in Cancer in European Union (Parenteral)